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Abstract. Aim: We assessed feasibility of the transanal
minimally invasive surgery (TAMIS) procedure and quality of
life postoperatively. Patients and Methods: A total of 28 patients
with rectal lesions were treated using TAMIS at Southmead
Hospital, North Bristol NHS Trust. Outcome measures included
feasibility of excision, negative margin (R0) resection rate,
length of hospital stay, morbidity and mortality, and
postoperative quality of life associated with anal incontinence.
Results; TAMIS was feasible in 90% of cases. R0 resection was
82%. The mean length of hospital stay was 1.5 days. Six (21%)
patients experienced acute urinary retention postoperatively.
One (4%) patient was re-admitted with rectal bleeding. One
patient experienced a perforation. Mortality was 0%.
Postoperative quality of life indicated low severity of symptoms
of anal incontinence. Conclusion: This study demonstrates that
TAMIS is a feasible option in the treatment of rectal tumours
and does not impair quality of life postoperatively. 
Over the past 5 years, transanal surgery has increasingly
been described using standard laparoscopic instruments
through a single port. This was first described using the
single incision port (SILS, Covidien, Minneapolis, MN,
USA) (1) and following on from this the Gel Point Path port
(Applied Medical, CA, USA) has been adapted specifically
for the transanal minimally invasive surgery (TAMIS)
technique. The costs are much lower and more accessible for
the average colorectal unit than use of transanal endoscopic
microsurgery (TEM) (2). The safety and efficacy of the
TAMIS approach has been reported in small case series
worldwide (3-11). However, the TAMIS approach is
currently not yet validated in the treatment of early rectal
cancer with larger-scale and longer follow-up studies. 
Current national UK guidelines recommend radical total
mesorectal excision (TME) as the gold standard of treatment for
rectal cancer (12). Trials are underway comparing the
oncological outcomes of TME with local excision and
radiotherapy (13). Alongside this, use of transanal TAMIS
alongside laparoscopic TME (TaTME) is gaining popularity in
the treatment of low rectal cancer. These cases are well known
to be challenging, particularly in the male irradiated pelvis. The
recent Association of Coloproctology of Great Britain and
Ireland Consensus Statement of the TaTME technique for low
rectal cancer have concluded that there is a steep learning curve
associated with transanal laparoscopic surgery (14). The Oxford
study reported a mean operative time of 315.3 min and have
recommended that only surgeons trained in the laparoscopic
transanal platform attempt TaTME surgery (15).
Functional bowel disturbance after rectal cancer surgery
has been reported in up to 45% of patients at 12 months (16).
Chronic symptoms, such as anal incontinence, can have a
significant impact on quality of life. The risk of anal
sphincter disturbance with local excision of rectal tumours
has been reported (14). The functional outcome of patients
undergoing the TAMIS procedure, however, has not been
evaluated to our knowledge. 
We describe the Bristol TAMIS series and evaluate: i)
feasibility of excision of rectal lesions excised using this
technique, ii) negative margin resection rate (R0), iii) length
of stay, iv) morbidity and mortality, and v) quality of life
associated with anal incontinence.
Patients and Methods
A total of 28 consecutive patients underwent TAMIS for excision
of a rectal tumour between March 2013 and May 2015. All cases
were undertaken by a single surgeon at a teaching hospital in North
Bristol, UK. All patients had undergone prior endoscopic evaluation
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of rectal lesions. In benign cases, patients were offered this
technique as an alternative to endoscopic mucosal resection (EMR).
In malignant cases, the patients were assessed as unfit for TME and
offered this procedure as palliation.
All patients received full bowel preparation on the day prior to
the procedure (Moviprep, Salix, NC, USA). All surgeries were
performed under general anaesthesia in the Lloyd Davies supine
position. A Gel Point Path port was used in the majority of cases, a
SILS port for the remainder. 
Upon insertion, the obturator was removed and the port swiftly
inserted with the use of a Hill Ferguson retractor. A pneumorectum
was established with 15 mmHg CO2 and maintained at 40 mmHg
per min. A 10 mm 30-degree laparoscope, Maryland forceps,
laparoscopic hook diathermy and high-energy device were used.
Submucosal dissection was performed en bloc for the larger carpet
adenomas. Otherwise, a full-thickness disc resection was performed
with a 1 cm margin of healthy tissue. All full-thickness defects were
repaired using a continuous locking absorbable suture.
All patients underwent endoscopic evaluation at 3 months.
Quality of life associated with anal incontinence was assessed
during follow-up using the quality-of-life section (questions 19-23)
from the International Consultation on Incontinence Modular
Questionnaire (ICIQ) bowel symptoms questionnaire. This
questionnaire is patient-reported and has been validated for use in
patients who experience faecal incontinence due to solid, liquid or
flatus (17).
Results
A total of 28 patients underwent this technique, 50% were
females and 50% males (Table I). The median age of patients
was 73 years (range=51-91 years). In three cases, it was not
possible to remove the rectal lesion successfully using the
TAMIS procedure. In one case, a 90-mm carpet adenoma
was found to occupy 75% of the circumference of the lumen
and so TAMIS was abandoned in favour of a laparoscopic
anterior resection. In the second case, a 12 mm rectal cancer
was seen above the recto-sigmoidal junction. This lesion was
inaccessible using TAMIS and the procedure was converted
to a laparoscopic anterior resection. The third case was a
planned palliative de-bulking of rectal cancer. This tumour
was extensive and remained incomplete (R2) due to
extensive size. The patient underwent palliative radiotherapy
and died 12 months later. 
Benign lesions. Overall, 17 benign rectal polyps were
removed. The median size of lesions was 50 mm (range=12-
115 mm). Treatment intent was curative in 16/17 cases.
Twelve out of 17 (71%) cases had a negative resection
margin (R0). There were five patients with a positive
resection margin (R1). These cases were the larger carpet
adenomas with an average size of 57 mm (range=40-93 mm).
At this size, the EMR technique would have been performed
in a piecemeal fashion and perhaps over several sittings.
Resection margins under these circumstances cannot usually
be assessed pathologically.
One patient (6%) was diagnosed with a polyp recurrence
at follow-up which was removed endoscopically. One patient
declined follow-up.
Rectal cancer. A total of 11 malignant rectal lesions were
removed. The median size of lesions was 43 mm (range=12-
95 mm). Treatment intent was palliative in 9/11 cases (82%).
In one benign case, an unexpected Haggitt 1 cancer was
diagnosed with a 12 mm margin (R0). This patient opted for
close endoscopic surveillance. One (10%) case had a close
resection margin of 0.4 mm. This occurred in a patient with
a large adenoma with an unexpected cancer diagnosis. Where
lesions were known to be malignant, R0 was 100%. One
patient (9%) experienced a recurrence of rectal cancer 11
months after the TAMIS procedure and has been referred for
palliative radiotherapy; she is still unfit for radical surgery.
The mean length of stay for patients overall after
successful TAMIS procedure was 1.5 days (range=0-4 days).
After 15 cases were performed, we found it unnecessary to
keep patients in hospital overnight for observation. We are
now more likely to perform this operation as a day case
procedure. 
Two patients (7%) experienced postoperative urinary
retention and were discharged home with an indwelling
catheter bag. In all cases, successful catheter removal took
place at a later date, with one patient needing to undergo a
transurethral resection of the prostate. Four patients
developed urinary retention postoperatively; all four cases
resolved prior to discharge. As a result of these urinary
complications, all subsequent patients underwent a one-off
‘in-out’ catheterisation at the start of the procedure. This
modification has resulted in reduced incidence of
postoperative urinary retention. 
One patient (4%) was re-admitted 2 weeks after the
TAMIS procedure with acute rectal bleeding. He underwent
an examination under general anaesthesia and no obvious
bleeding point was seen. The bleeding resolved
conservatively. He was taking oral anticoagulants and so was
thought to be at higher risk of bleeding.
One patient (4%) experienced a full-thickness perforation
during the TAMIS procedure. The tumour was located at the
recto-sigmoidal junction. A full-thickness approach was
planned in this case as the tumour was a non lifting polyp. At
the time of perforation, it was possible to directly suture the
defect without converting to laparoscopic or open abdominal
surgery. The patient was discharged as planned the next day,
with a 5-day course of broad-spectrum antibiotics. The
pathology of the specimen was a 1.5 cm diverticular abscess.
The lesion had not been biopsied preoperatively as it was felt
to be at high risk for adenocarcinoma.
The 30-day mortality was 0%.
Overall, 50% of patients (13/26) responded to the ICIQ
bowel symptoms questionnaire. Two patients (8%) had died
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before the questionnaire follow-up due to subsequent
medical diagnoses. The quality-of-life section of the
questionnaire involves answering five questions about self-
perceived impact of anal incontinence and symptom severity.
A higher score indicates increasing severity of symptoms.
The highest possible score is 60. In this sample, the median
score was 15 (Table II). A total of 11/13 patients scored
under 30, and two patients had scores outlying at 36 and 53.
Discussion
In this all-inclusive transanal series from Bristol, we report
increasing success rates of the TAMIS technique in older
patients with rectal cancer who were deemed unfit for radical
surgery by TME. We report a 90% success rate in the
removal of larger rectal lesions that would traditionally not
fit the criteria for transanal excision. The benefit to the
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Table I. Outcome data.
No. Gender Age Curative Size of Clear Complications Follow-up
(years) intent lesion margins
Benign cases
1 F 75 Yes 65 mm Yes None Clear
2 M 65 Yes 33 mm Yes Urinary leg bag Clear
3 M 78 Yes 90 mm Yes Converted to laparoscopic Clear
anterior resection
4 M 70 Yes 33 mm Yes Urinary leg bag Clear
5 F 82 Yes 115 mm Yes None Clear
6 M 75 Yes 25 mm Yes None Clear
7 M 81 Yes 45 mm No Bleed 2 weeks post procedure. Clear
Resolved conservatively
8 F 66 Yes 40 mm Yes None Clear
9 F 86 No 40 mm No None Declined
10 M 81 Yes 62 mm No Stricture requiring Clear
endoscopic dilatation
11 M 63 Yes No residual Yes None Clear
disease
12 F 68 Yes 50 mm Yes None Polyp recurrence – 
snared endoscopically
13 M 74 Yes 45 mm No None Clear
14 M 74 Yes 30 mm Yes None Clear
15 F 62 Yes 93 mm No None Clear
16 M 75 Yes 12 mm Yes Sigmoid perforation Clear
sutured at operation
17 M 77 Yes 15 mm Yes None Clear
Malignant cases
18 F 51 Yes 45 mm Yes None Clear
19 F 79 No 61 mm Yes None Clear
20 F 69 No 28 mm Yes None clear
21 F 70 No 13 mm Yes None Clear
22 F 85 No 43 mm Yes Converted to open Recurrent 
anterior resection rectal cancer
23 M 75 No 43 mm Yes None Clear
24 M 91 No 95 mm No Converted to endoscopic Required further 
de-bulking procedures endoscopically
25 F 87 No 30 mm Yes Persistent temperature Clear
requiring antibiotics
26 F 57 No 30 mm Yes Urinary retention Recurrent cancer at 11 months. 
Palliative radiotherapy 
given as unfit for surgery
27 M 85 No 12 mm Yes Failed TAMIS converted to Clear
laparoscopic anterior resection
28 F 52 Yes 52 mm 0.4 mm Small focus of invasion Early elective laparoscopic 
within carpet adenoma anterior resection performed
M: Male; F: female. 
patient is that removal of their rectal tumour can be achieved
in one sitting by TAMIS. 
Transanal excision of rectal tumours as a definitive
treatment option for rectal cancer may only be suitable for a
select group of patients. This is due to an unacceptably high
rate of local recurrence of up to 47% (18). Radical TME still
remains the definitive treatment option for rectal cancer;
however, we are increasingly treating older patients who may
be too unfit to undergo radical surgery with the possibility
of a stoma (19). The GRECCAR 2 trial aims to assess local
excision in down-staged T2/3rectal cancer in fit patients. It
may hopefully identify a group of patients based on clinical
response for whom local excision and neoadjuvant treatment
carries the most benefit (20). 
Our results compare favourably with endoscopic removal.
At 5 cm in size for benign lesions and 4 cm for
malignancies, these lesions would be classified as complex
according to the British Society of Gastroenterology
guidelines (21). In these latest guidelines, removal of
tumours over 4 cm in size should only be undertaken by
clinicians with sufficient expertise. This is due to the high
risk of adverse events occurring, such as bleeding or
perforation. Certainly use of the EMR technique would not
permit margin assessment and may necessitate multiple
procedures to safely remove one larger lesion. For lesions
this size, endoscopic submucosal dissection has gained
popularity, however, it is a highly specialized procedure that
is currently only offered in a few centres in the UK. It is
associated with a lower R0 resection rate of 70%, however,
risk of perforation is higher than that associated with the
TAMIS procedure (22).
Local excision of rectal tumours using TEM has been
associated with anal sphincter disturbance (14). Anal
sphincter disturbance after TEM may be attributed to the
large size of the TEM microscope, however, functional
outcome data are mixed, with some studies reporting no
disturbance in function (23). Potentially, such disturbance in
function may be due to the duration of the operation. For
TEM procedures, this has been reported to be103 min (24).
All 28 of our cases required less than 60 min transanal
operating time. 
Our postoperative quality-of-life results demonstrate that
the functional outcome after this type of surgery is, overall,
within acceptable limits. Ideally, we would have liked an
increased response rate to our questionnaire. The majority of
non-responders were over 75 years old and may have found
that method of communication difficult. One study assessed
anal sphincter injury after TAMIS using endo-anal ultrasound
and found this to be negligible (4). Quality of life as a result
of functional anal disturbance has not been investigated
before as far as we are aware, and larger studies with longer
follow-up data would need to be undertaken to investigate
this question further. 
Our study is the first UK series to attempt this technique
for all rectal lesions, regardless of size. Our results point
towards increasing indications for TAMIS other than a rectal
lesion of 3 cm or less in the mid to upper rectum, preferably
posteriorly placed. Our series has shown that the TAMIS
procedure may be attempted in more extensive lesions when
en-bloc removal is desirable. Broadening the indications for
this procedure will also have the benefit of gaining valuable
laparoscopic transanal operating exposure for colorectal
surgeons looking to perform TaTME at a later stage.
Overall the associated morbidity, even in the older patient,
appears to be within acceptable limits. Whilst it is exciting
to think that this technique may be suitable for definitive
rectal cancer treatment, its real advantage is in surgical
management of rectal lesions in the older patient where
curative intent is not always the main priority. In this group
of patients, the inconvenience of multiple snare removals
endoscopically or the risks of radical surgery can outweigh
the benefits in terms of major morbidity and mortality. 
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